Established in 2018, Worg Pharmaceuticals (Zhejiang) Co., Ltd. is a global, commercialization-stage biopharmaceutical company dedicated to developing next-generation specific immunotherapies for allergic and autoimmune diseases.

With a focus on building revolutionary innovation platforms and integrating global resources, the company aims to provide world-class, end-to-end diagnostic and therapeutic solutions for patients. It operates R&D centers and laboratories in Shanghai and Madrid, along with a fully integrated subsidiary in Europe covering production, research, and commercialization.

Through a “proprietary R&D + global partnerships” model, the company has built a comprehensive product pipeline spanning diagnostics and treatment. Over 20 allergy diagnosis and treatment products are already commercialized in Europe and globally, while clinical registration and commercialization efforts are underway in China, Japan, Germany, the U.S., and other key markets. Additionally, more than 10 innovative pipeline products are advancing through preclinical and clinical development.